Common questions about Admelog (FAQ)
Q: How quickly is Admelog expected to start working after injection?
A: Admelog is classified as a rapid-acting insulin analog. Official product information indicates that the active ingredient, insulin lispro, typically begins its glucose-lowering action approximately 10 to 20 minutes after being administered by subcutaneous injection.
Q: What is the typical duration of action for Admelog?
A: The duration of activity for insulin lispro is generally described as being 2 to 5 hours. However, regulatory documents state that the actual duration of action for any insulin can vary considerably from person to person. Factors like the dose amount, the chosen injection site, and a person's physical activity level all influence how long the effects last.
Q: What's the main difference between Admelog and other rapid-acting insulins?
A: Admelog contains insulin lispro and is classified as a biosimilar to the original, reference insulin lispro product. Official documentation confirms that Admelog is highly similar to the reference product and that there are no clinically meaningful differences in its efficacy (how well it works) or safety profile.
Q: Does Admelog come in a pen or a vial?
A: Yes, Admelog is supplied as a solution for injection in two main formats. It is available in standard vials that require a syringe, and it also comes in a pre-filled disposable pen called the SoloStar pen.
Q: Is Admelog safe to use during pregnancy?
A: Regulatory documents describe use during pregnancy if clinically indicated. Available data has not established an association between insulin lispro and major adverse fetal outcomes. Such use is generally accompanied by intensified monitoring of blood glucose levels.
Q: Can Admelog be used in an insulin pump?
A: Yes, Admelog is approved for use by continuous subcutaneous infusion, which is the method used in appropriate insulin pump systems. Use in a pump requires following the specific instructions for the infusion set and system.
Q: What is the difference between Admelog and Admelog Solostar?
A: Admelog is the name of the medicine itself, which is the insulin lispro solution. Admelog SoloStar is the brand name of the disposable prefilled pen device that is used to deliver the Admelog solution for injection.
Q: Does the injection site affect how well Admelog works?
A: Yes. Official information on the drug's activity shows that the rate of absorption and the overall time course of action can depend on the chosen injection site. Rotation of sites is documented as important to help ensure consistent absorption and reduce the risk of tissue changes.
Q: How soon after taking Admelog should I eat?
A: Admelog is designed as a mealtime insulin to match the rise in glucose that occurs after eating. Official administration guidelines state that it should be administered by subcutaneous injection within 15 minutes before a meal or immediately after a meal.
Q: Is it possible to be allergic to Admelog?
A: Yes, it is possible. Official regulatory documentation states that Admelog is contraindicated (should not be used) if a person has a known hypersensitivity or allergy to insulin lispro or any other ingredient in the formulation. While localized allergic reactions are common, serious, body-wide allergic reactions are classified as a rare event.
Q: Does stress or illness change how Admelog works?
A: Official safety information notes that physical conditions, such as illness or infection, can affect blood glucose levels. When conditions change, such as during periods of illness, the individualized insulin regimen may require adjustment.
Q: Can Admelog affect blood pressure?
A: Admelog's official profile documents that it interacts with several medicines used to manage blood pressure. For example, some blood pressure medications, like ACE inhibitors, may enhance the glucose-lowering effect of Admelog, while other medicines, like diuretics, may decrease it.
Q: How does travel affect the use and storage of Admelog?
A: Regulatory documents provide specific instructions for the storage conditions and temperature limits for Admelog. When traveling, maintaining these conditions is important. Furthermore, changes in routine, particularly those involving time zones, may require an adjustment of the individualized insulin regimen.
Q: Is Admelog designed to be taken right before or right after a meal?
A: Yes, it is designed for meal coverage. Official regulatory instructions state that Admelog should be administered by subcutaneous injection within 15 minutes before a meal or immediately after a meal to control post-meal blood sugar.
Q: Is Admelog the same as Humalog (insulin lispro)?
A: Admelog is a follow-on biologic product containing insulin lispro, making it a biosimilar to the insulin lispro reference drug, which is Humalog. Regulatory bodies, after review, have determined that Admelog is highly similar with no clinically meaningful differences in efficacy or safety.
Q: How is the risk of low blood sugar managed when using Admelog?
A: Official risk mitigation strategies focus heavily on patient and caregiver education. These strategies emphasize the importance of self-monitoring of blood glucose and recognizing the signs and symptoms of low blood sugar (hypoglycemia).
Q: Are there any specific foods or drinks that interact with Admelog?
A: Regulatory documentation specifically mentions that the effect of alcohol is unpredictable and may cause either an increase or a decrease in the glucose-lowering effect. While the timing of food is essential for using Admelog, food itself is not listed as a contraindicative interaction.
Q: Can Admelog be mixed with other types of insulin?
A: Official administration instructions state that Admelog is not to be mixed with any other insulin or diluent when administered using a continuous subcutaneous infusion pump. The product labeling for the vial format does not generally support mixing with other insulins.
Q: Do over-the-counter pain relievers interact with Admelog?
A: Official documentation notes that medicines containing Salicylates, a class of drugs found in some common over-the-counter pain relievers, may lead to an enhanced glucose-lowering effect. This interaction could potentially increase the risk of hypoglycemia (low blood sugar).
Q: Is it normal to feel tired when first starting Admelog?
A: Adverse reaction documentation for insulin lispro has reported instances of general discomfort, including feeling fatigue and unusual tiredness or weakness in some patients. This is not listed as a 'very common' effect, but it has been documented.
Q: Are there different strengths of Admelog available?
A: Yes, Admelog is officially available in two strengths of solution for injection. These are U-100 (100 units/mL) and a more concentrated formulation, U-200 (200 units/mL).
Q: What signs of an allergic reaction to Admelog should I look out for?
A: Systemic allergic reactions are rare but serious. Documented signs to look out for include trouble breathing or swallowing, a fast heartbeat, and swelling of the face, hands, or mouth.
Q: Are there any long-term side effects associated with using Admelog?
A: Changes to the fatty tissue under the skin, called lipodystrophy, are linked to long-term administration at non-rotated injection sites. Key comparative trials had limited follow-up, indicating limited available information for long-term outcomes spanning many years.
Q: Does Admelog have a generic version?
A: Admelog is classified as a follow-on biologic (biosimilar) of the reference product Humalog. The non-proprietary name for the active substance is insulin lispro.
Q: What types of activity level changes might affect Admelog's action?
A: Official safety warnings note that changes in the level of physical activity may increase the risk of hypoglycemia (low blood sugar). Changes in activity are a factor that may be considered for adjustment of the individualized insulin dose.
Q: Is it normal to feel a sting or burning sensation when injecting Admelog?
A: Official documentation lists common injection site reactions such as redness, swelling, or itching. The presence of pain or discomfort, which may feel like a sting or burn, has also been documented at the injection site.
Q: Can Admelog cause changes in vision?
A: Safety information indicates that the rapid improvement in glucose control that can occur when starting insulin is associated with a temporary worsening of diabetic retinopathy (an eye condition). Additionally, blurred vision is a documented symptom of hypoglycemia.
Q: What is the role of Admelog in a basal-bolus regimen?
A: Admelog, as a rapid-acting insulin analog, functions as the bolus insulin component in a basal-bolus regimen. Bolus insulin is given specifically to cover the acute glucose load from meals (mealtime insulin).
